Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr130.00 DKK
Change Today +3.50 / 2.77%
Volume 100.4K
ZEAL On Other Exchanges
Symbol
Exchange
Copenhagen
Berlin
OTC US
As of 11:06 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

zealand pharma a/s (ZEAL) Snapshot

Open
kr128.00
Previous Close
kr126.50
Day High
kr130.00
Day Low
kr127.50
52 Week High
07/30/15 - kr166.00
52 Week Low
10/16/14 - kr58.00
Market Cap
3.1B
Average Volume 10 Days
151.0K
EPS TTM
kr-2.87
Shares Outstanding
23.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZEALAND PHARMA A/S (ZEAL)

Related News

No related news articles were found.

zealand pharma a/s (ZEAL) Related Businessweek News

No Related Businessweek News Found

zealand pharma a/s (ZEAL) Details

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide medicines in Denmark. It offers Lyxumia (Lixisenatide), a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes. The company is also developing Lantus (LixiLan), which is in Phase III clinical trials for the treatment of type 2 diabetes; Danegaptide that is in Phase II clinical trials to treat cardiac reperfusion injuries; and Elsiglutide, a GLP-2 receptor agonist, which is in Phase IIb clinical trials for the treatment of chemotherapy-induced diarrhea in patients with colorectal cancer. In addition, it is developing ZP4207 that is in Phase I clinical trials to treat hypoglycemia in diabetes; and ZP2929, a dual acting glucagon/GLP-1 peptide receptor agonist, which is in Phase I clinical trials for the treatment of diabetes and/or obesity. The company has license agreements and partnerships with Sanofi S.A., Helsinn Healthcare S.A., Boehringer Ingelheim International GmbH, and Eli Lilly. Zealand Pharma A/S was founded in 1997 and is based in Copenhagen, Denmark.

109 Employees
Last Reported Date: 08/28/15
Founded in 1997

zealand pharma a/s (ZEAL) Top Compensated Officers

Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: kr2.1M
Compensation as of Fiscal Year 2014.

zealand pharma a/s (ZEAL) Key Developments

Zealand Pharma A/S Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Zealand Pharma A/S reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of DKK 7,061,000 against DKK 4,294,000 a year ago. Operating loss was DKK 64,568,000 against DKK 48,112,000 a year ago. Loss from ordinary activities before tax was DKK 79,002,000 against DKK 47,741,000 a year ago. Net loss for the period (after tax) was DKK 76,807,000 or DKK 3.39 per diluted share against DKK 47,741,000 or DKK 2.10 per diluted share a year ago. For the six months, the company reported revenue of DKK 13,400,000 against DKK 89,241,000 a year ago. Operating loss was DKK 114,081,000 against DKK 19,504,000 a year ago. Loss from ordinary activities before tax was DKK 134,550,000 against DKK 18,891,000 a year ago. Net loss for the period (after tax) was DKK 132,355,000 or DKK 5.79 per diluted share against DKK 18,891,000 or DKK 0.83 per diluted share a year ago. Cash flow used in operating activities was DKK 118,826,000 against DKK 10,826,000 a year ago. Purchase of property, plant and equipment was DKK 1,815,000 against DKK 2,036,000 a year ago.

Zealand Pharma A/S, H1 2015 Earnings Call, Aug 28, 2015

Zealand Pharma A/S, H1 2015 Earnings Call, Aug 28, 2015

Zealand Announces Clinical Phase I trial Results of Glucagon Analogue, ZP4207

Zealand announced results from a clinical Phase I trial with a single-dose version of its novel, stable glucagon analogue, ZP4207. ZP4207, invented and wholly-owned by Zealand, is suited for liquid formulation and has in preclinical studies shown promising potential as a more convenient ready-to-use rescue pen for the treatment of severe hypoglycemia. Zealand initiated the ZP4207 single-dose Phase I trial in November 2014 as a two-part study to evaluate safety and tolerability in both healthy volunteers and Type 1 diabetes patients. The enrollment and treatment of 64 healthy volunteers and 20 patients with Type 1 diabetes was completed ahead of schedule. Based on the results from the trial, Zealand will now progress the development of ZP4207 for severe hypoglycemia towards the next clinical phases. The first-in-man Phase I trial comprised two parts: In Part 1, Zealand enrolled 64 healthy volunteers who were treated with single-ascending doses of ZP4207 primarily to evaluate safety and tolerability and secondarily to evaluate various pharmacokinetic and pharmacodynamic measurements compared to a marketed glucagon hypoglycemia rescue treatment. Results showed that ZP4207 was safe and well tolerated across all doses evaluated (0.01 mg to 2.0 mg per subject). Furthermore, blood glucose levels were increased as expected across a broad dose range; In Part 2 of the trial, the same endpoints were evaluated for a selected single dose of ZP4207 in 20 patients with Type 1 diabetes. The patients were challenged with insulin into hypoglycemia before treatment with ZP4207 to get an indication of the efficacy of ZP4207 to release glucose stores and increase blood glucose levels in a cross-over design with a marketed glucagon rescue treatment as direct active comparator. Results showed that ZP4207 was also safe and well tolerated in patients with Type 1 diabetes. In addition, ZP4207 showed the expected effects on raising blood glucose levels after insulin induced hypoglycemia and similar to the effects of marketed glucagon.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEAL:DC kr130.00 DKK +3.50

ZEAL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZEAL.
View Industry Companies
 

Industry Analysis

ZEAL

Industry Average

Valuation ZEAL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 37.1x
Price/Book 17.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 28.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZEALAND PHARMA A/S, please visit zealandpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.